



P H A R M A U K L T D

Patient Organisation Disclosure – Methodological Note

This disclosure has been prepared in accordance with the Irish Pharmaceutical Healthcare Association (IPHA) Code of Practice for the Pharmaceutical Industry and relates to support provided to patient organisations during the reporting period.

Reporting Period

This disclosure covers transfers of value made between 1 January 2025 and 31 December 2025.

Scope

The disclosure includes financial and non-financial support provided directly or indirectly to patient organisations. Such support may include, but is not limited to:

Donations and grants.

Sponsorship of meetings, events, or educational activities.

Support for disease awareness, patient education, or advocacy initiatives.

Fees for services provided by patient organisations.

Joint projects or collaborative initiatives.

Contributions towards the development of educational materials or resources.

Other forms of support permitted under the IPHA Code of Practice.

Disclosure Methodology

Transfers of value are disclosed on an individual patient organisation basis and include a description of the nature of the support provided and the associated monetary value.

Where support has been provided in kind rather than as direct financial payment, the value disclosed represents a reasonable estimate of the benefit provided.

The disclosure reflects support provided during the reporting period, irrespective of when the associated activity or project took place.

Recipient Organisations

This disclosure includes all patient organisations that received support from the Company during the reporting period.

